Apparatus for continuous directed evolution of proteins and nucleic acids

Patent metadata

Field	Value
Publication number	US-9771574-B2
Application number	US-201514704226-A
Country	US
Kind code	B2
Filing date	May 5, 2015
Priority date	Sep 5, 2008
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

Aspects of the disclosure relate to an apparatus for continuous directed evolution of a gene of interest. In some embodiments, the apparatus comprises a cellstat and a turbidostat. In some embodiments, the apparatus is useful in methods of passing a nucleic acid from cell to cell in a desired function-dependent manner.

First claim

The invention claimed is:

1. An apparatus for continuous evolution of a gene of interest, the apparatus comprising
(a) a cellstat comprising
(i) a cell culture vessel comprising a population of host cells wherein the host cells comprise phage genes required to package a selection phagemid into infectious phage particles,
(ii) a population of phages comprising the gene of interest to be evolved, wherein the population of phages is capable of infecting the host cells and introducing the gene of interest to be evolved into the host cells, wherein at least one of the phage genes required to package the selection phagemid into infectious phage particles is expressed in response to expression of the gene of interest to be evolved in the host cells;
(iii) an inflow connected to a turbidostat;
(iv) a drain to waste;
(v) a pump effecting a flow of host cells through the cellstat, wherein the flow rate of the host cells through the cellstat permits replication of the phage, but not of the host cells, in the cellstat; and

(b) a turbidostat comprising
(i) a population of uninfected host cells maintained at a substantially constant cell density; and
(ii) an outflow connected to the inflow of the cellstat.

2. The apparatus of claim 1 , wherein the apparatus further comprises
(c) a vessel comprising a mutagen in liquid form.

3. The apparatus of claim 1 , wherein the phages are filamentous phages.

4. The apparatus of claim 1 , wherein the phages are M13 phages.

5. The apparatus of claim 1 , wherein the selection phagemid comprises the at least one phage gene required to package the selection phagemid into infectious phage particles.

6. The apparatus of claim 1 , wherein the host cells comprise:
a helper plasmid comprising a phage genome in which at least one gene required to package the selection phagemid into phage particles is disabled; and
an accessory plasmid comprising the gene required to package the selection phagemid into phage particles that is disabled in the helper plasmid, wherein the gene is expressed from the accessory plasmid in response to expression of the gene to be evolved.

7. The apparatus of claim 6 , wherein the gene required to package the selection phagemid into phage particles is gene II protein (g2p), gene III protein (g3p), or gene VI protein (g6p).

8. The apparatus of claim 6 , wherein the phage genome is selected from the group consisting of an M13 phage genome, an fd page genome, an fl phage genome, a ZJ/2 phage genome, an Ec9 phage genome, an AE2 phage genome, an HR phage genome, a δA phage genome, and an Ike phage genome.

9. The apparatus of claim 2 , wherein said mutagen is selected from the group consisting of nucleotide analogues, nucleoside precursors, alkylating agents, cross-linking agents, genotoxins, and radiation.

10. The apparatus of claim 2 , wherein said mutagen is a chemical mutagen.

11. The apparatus of claim 10 , wherein said chemical mutagen is selected from the group consisting of 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) (CAS no. 77439-76-0), O,O-dimethyl-S-(phthalimidomethyl)phosphorodithioate (phos-met) (CAS no. 732-11-6), formaldehyde (CAS no. 50-00-0), 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) (CAS no. 3688-53-7), glyoxal (CAS no. 107-22-2), 6-mercaptopurine (CAS no. 50-44-2), N-(trichloromethylthio)-4-cyclohexane-1,2-dicarboximide (captan) (CAS no. 133-06-2), 2-aminopurine (CAS no. 452-06-2), methyl methane sulfonate (MMS) (CAS No. 66-27-3), 4-nitroquinoline 1-oxide (4-NQO) (CAS No. 56-57-5), N4-Aminocytidine (CAS no. 57294-74-3), sodium azide (CAS no. 26628-22-8), N-ethyl-N-nitrosourea (ENU) (CAS no. 759-73-9), N-methyl-N-nitrosourea (MNU) (CAS no. 820-60-0), 5-azacytidine (CAS no. 320-67-2), cumene hydroperoxide (CHP) (CAS no. 80-15-9), ethyl methanesulfonate (EMS) (CAS no. 62-50-0), N-ethyl-N-nitro-N-nitrosoguanidine (ENNG) (CAS no. 4245-77-6), N-methyl-N-nitro-N-nitrosoguanidine (MNNG) (CAS no. 70-25-7), 5-diazouracil (CAS no. 2435-76-9) and t-butyl hydroperoxide (BHP) (CAS no. 75-91-2).

12. The apparatus of claim 1 , wherein the host cells are engineered to inducibly express SOS mutagenizing lesion-bypass proteins.

13. The apparatus of claim 12 , wherein the SOS mutagenizing lesion-bypass proteins are selected from the group consisting of polymerase V and activated recA.

14. The apparatus of claim 1 , wherein the host cells comprise a mutagenic plasmid capable of inducibly expressing an error-prone DNA polymerase subunit.

15. The apparatus of claim 14 , wherein the apparatus comprises a vessel comprising an agent inducing expression of the SOS mutagenizing lesion-bypass proteins from the mutagenic plasmid.

16. The apparatus of claim 15 , wherein the agent inducing expression of the SOS mutagenizing lesion-bypass proteins from the mutagenic plasmid is arabinose.

17. The apparatus of claim 6 , wherein a gene required to package the selection phagemid into phage particles that is disabled in the helper plasmid is inducibly expressed from the accessory plasmid.

18. The apparatus of claim 1 , wherein the host cells comprise a system of transferring nucleic acids from one cell to another via phage infection.

19. The apparatus of claim 4 , wherein the M13 phages do not comprise a full-length pIII gene.

20. The apparatus of claim 1 , wherein the host cells are prokaryotic cells amenable to phage infection, replication, and production.

21. The apparatus of claim 1 , wherein the host cells are E. coli cells.

Assignees

• Harvard College

Inventors

• Liu David R
• Esvelt Kevin Michael

Classifications

• C12N15/1058 Primary

  Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms · CPC title

• C12N15/1024

  In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair · CPC title

• C12N15/1037

  Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title